AK139

Phase 2Small molecule

AAkeso

AK139 is one of 62 small molecule programs targeting Asthma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AsthmaNot yet recruiting

Prurigo NodularisNot yet recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Not yet recruiting

Seasonal Allergic RhinitisNot yet recruiting

AsthmaPhase 2

Not yet recruiting

Prurigo NodularisPhase 2

Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)Phase 2

Not yet recruiting

Seasonal Allergic RhinitisPhase 2

Not yet recruiting

Competition

Competitive Landscape

161 competitors in Asthma

#DrugCompanyPhaseTrials

AK139

AAkeso

Phase 2

1 2

Arcoxia

DUPIXENT

1 4

Atrovent

Boehringer Ingelheim

Preclinical

2 5

Ozone

TTanta University

Preclinical

1 6

Lexapro

SShirley Ryan AbilityLab

Preclinical

1 7

Biological Drug

UUniversitaire Ziekenhuizen KU Leuven

Preclinical

1 8

Guanidine Hydrochloride

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Rhinovirus

UUniversity of Virginia

Preclinical

2 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Not yet recruiting

Asthma

NCT07436221

Q2 2027

Phase 2Not yet recruiting

Seasonal Allergic Rhinitis

NCT07436234

Q3 2027

Phase 2Not yet recruiting

Chronic Rhinosinusitis With Nasal Polyps (crswnp)

NCT07755371

Phase 2Not yet recruiting

Prurigo Nodularis

NCT07883213

Q1 2029

Phase 2Not yet recruiting

Chronic Spontaneous Urticaria

NCT07875426

Clinical

Trials by Indication[1]

Seasonal Allergic Rhinitis1 trial

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Seasonal Allergic Rhinitis

Not yet recruiting·AAkeso·Phase 2·NCT07436234·111 enrolled

Asthma1 trial

A Study to Evaluate the Efficacy and Safety of AK139 in Participants With Asthma

Not yet recruiting·AAkeso·Phase 2·NCT07436221·160 enrolled

Prurigo Nodularis1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AK139 in Subjects With Prurigo Nodularis

Not yet recruiting·AAkeso·Phase 2·NCT07883213·132 enrolled

Chronic Spontaneous Urticaria1 trial

A Multicenter, Phase II Clinical Trial to Evaluate the Efficacy and Safety of AK139 Injection in Patients With Chronic Spontaneous Urticaria

Not yet recruiting·AAkeso·Phase 2·NCT07875426·201 enrolled

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating the Efficacy and Safety of AK139 in Participants With Chronic Rhinosinusitis With Nasal Polyps

Not yet recruiting·AAkeso·Phase 2·NCT07755371·75 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for AK139. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AK139 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AK139. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Akeso company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAkeso

AK139

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q1 2029

Trials by Indication[1]

Seasonal Allergic Rhinitis1 trial

Asthma1 trial

Prurigo Nodularis1 trial

Chronic Spontaneous Urticaria1 trial

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)1 trial

References

Drug Info

Quick Facts

Related News